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Abstract
To quantify the direct healthcare cost of systemic sclerosis (SSc) and identify its determinants. Healthcare use was captured
through data linkage, wherein clinical and medication data for SSc patients from the state of Victoria enrolled in the Australian
Scleroderma Cohort Study were linked with the Victorian hospital admissions and emergency presentations data sets, and the
Medicare Beneﬁts Schedule which contains all government subsidized ambulatory care services, for the period 2011-2015.
Medication cost was determined from the Pharmaceutical Beneﬁts Scheme. Costs were extrapolated to all Australian SSc patients
based onSSc prevalence of 21.1 per 100,000 and anAustralian population of 24,304,682 in 2015. Determinants of healthcare cost
were estimated using logistic regression. Total healthcare utilization cost to the Australian government extrapolated to all Australian
SSc patients from 2011 to 2015 was Australian Dollar (AUD)$297,663,404.77, which is an average annual cost of AUD
$59,532,680.95 (US Dollar [USD]$43,816,040.08) and annual cost per patient of AUD$11,607.07 (USD$8,542.80). Hospital
costs, including inpatient hospitalization and emergency department presentations, accounted for the majority of these costs
(44.4% of total), followed by medication cost (31.2%) and ambulatory care cost (24.4%). Pulmonary arterial hypertension (PAH)
and gastrointestinal (GIT) involvement were the major determinants of healthcare cost (OR 2.3 and 1.8, P= .01 for hospitalizations;
OR 2.8 and 2.0, P= .01 for ambulatory care; OR 7.8 and 1.6, P< .001 and P= .03 for medication cost, respectively). SSc is
associated with substantial healthcare utilization and direct economic burden. The most costly aspects of SSc are PAH and GIT
involvement.
Abbreviations: ASCS = Australian Scleroderma Cohort Study, AUD =Australian Dollar, dcSSc = diffuse cutaneous disease
subtype, DPMQ = dispensed price for maximum quantity, DRG = diagnosis related group, ED = emergency department, GIT =
gastrointestinal, IQR = interquartile range, lcSSc = limited cutaneous disease subtype, LOS = length of stay, MBS = Medicare
Beneﬁts Schedule, MSK = musculoskeletal system, PAH = pulmonary arterial hypertension, PBS = Pharmaceutical Beneﬁts
Scheme, RA = rheumatoid arthritis, SSc = systemic sclerosis, USD = US dollar, WIES = weighted inlier equivalent separation.
Keywords: ﬁnancial burden, healthcare utilization, scleroderma, systemic sclerosis
Editor: Raouf Hajji.
Authorship: KM: study design, data collection, data analysis, interpretation of results, and preparation of manuscript. WS: study design, data collection, interpretation of
results, and preparation of manuscript. JS, GN, NF, CH, SP, and MN: data collection, interpretation of results, preparation of manuscript. All authors have read and
approved the ﬁnal manuscript.
Funding/support: This work was supported by Scleroderma Australia, Arthritis Australia, Actelion Australia, Bayer, CSL Biotherapies, GlaxoSmithKline Australia and
Pﬁzer. MN holds a National Health and Medical Research Council of Australia Career Development Fellowship (APP 1126370). KM holds National Health and Medical
Research Council of Australia Postgraduate Scholarship (APP1113954).
The authors have no conﬂicts of interest to disclose.
Supplemental Digital Content is available for this article.
a Department of Medicine, The University of Melbourne at St Vincent’s Hospital (Melbourne), b Department of Rheumatology, St Vincent’s Hospital (Melbourne),
c Department of Medicine, Monash University, Clayton and Monash Health, Victoria, d Rheumatology Unit, Royal Adelaide Hospital, North Terrace, e Rheumatology Unit,
The Queen Elizabeth Hospital, Woodville Road, Woodville, f Discipline of Medicine, University of Adelaide, SA, Australia.
∗
Correspondence: Mandana Nikpour, Departments of Medicine, The University of Melbourne at St Vincent’s Hospital (Melbourne), 41 Victoria Parade, Fitzroy 3065,
Victoria, Australia (e-mail: m.nikpour@unimelb.edu.au).
Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Medicine (2017) 96:48(e8503)






Systemic sclerosis (SSc) is a chronic multisystem autoimmune
disease characterized by skin and internal organ ﬁbrosis.[1] It is
classiﬁed into limited (lcSSc) and diffuse cutaneous (dcSSc)
disease subtypes based on the extent of skin involvement.
Worldwide prevalence of SSc varies from 7/million to 489/
million,[1] with the reported prevalence in Australia being one of
the highest.[2]
Due to the progressive multiorgan nature of SSc long-term
follow-up and a multidisciplinary approach to patient care are
required. Therefore, it is not surprizing that SSc is one of the most
costly rheumatic diseases, with SSc patients utilizing more
healthcare dollars per annum than age and sex-matched
counterparts with rheumatoid arthritis (RA), psoriatic arthritis,
and/or inﬂammatory myopathies.[3–5]
Studies of healthcare utilization and economic burden speciﬁc
to SSc are scarce and those available are cross-sectional or
retrospective in nature, with small patient cohorts.[6–8] Economic
and health-related quality of life studies are essential for clinicians
and health policy makers in order to quantify the burden of
disease and to assess the outcomes of health policies and
interventions.
All Australian citizens and permanent residents have access to
public healthcare provided by a universal public health insurance
scheme named Medicare Australia, established in 1984 by the
Australian government. Medicare contributes to the costs of
inpatient treatment in public hospitals, the payment of beneﬁts
for professional health services listed on the Medicare Beneﬁts
Schedule (MBS) including the cost of ambulatory care services,
and subsidization of prescription medication cost under the
Pharmaceutical Beneﬁts Scheme (PBS).[9] Under Medicare, the
only out-of-pocket costs for patients are pharmacy dispensing
fees for medications and gap fees for ambulatory care in a private
setting where the amount charged by the healthcare provider
exceeds the MBS rebate.
The Australian hospital system includes public hospitals,
which are funded by the Australian government, and private
hospitals, which are funded by private health insurance and
compensation schemes. Public hospitals provide most of the
emergency department (ED) services (94%), outpatient services
(97%), and hospital admissions (60%). Although private
hospitals provide predominantly same day admissions (69%)
and elective surgery (66%), the complexity of hospital care
provided to admitted patients is similar in both public and private
hospitals.[9] Patterns of healthcare utilization are similar across
all Australian states.[9]
In order to determine the direct economic burden of SSc, we
sought to quantify total healthcare utilization and associated cost
inAustralianSSc patients from the state ofVictoriawhich accounts
for approximately 25% of the Australian population.[10]
2. Method
Consecutive patients in Victoria prospectively enrolled in the
Australian Scleroderma Cohort Study (ASCS), a multicenter
study of risk and prognostic factors for cardiopulmonary and
other clinically important outcomes in SSc, were included. The
ASCS contains comprehensive demographic, disease-related and
medication use data that are collected annually, and entered into
a custom-made database. Written consent was obtained from all
patients at recruitment and ethical approval was obtained from
the participating hospitals (St Vincent’s Hospital Melbourne and
Monash Health Melbourne).
2.1. Inclusion and exclusion criteria
We included all adult (>18 years) SSc patients recruited between
January 2011 and December 2015. Regardless of enrolment date
during this time, all healthcare costs between 2011 and 2015 for
each patient were included in the data linkage described below.
Although the ASCS is a nationwide study, Victoria was chosen as
it is Australia’s most populous state, comprises the majority of
patients enrolled in ASCS, and has themost complete clinical data
entered in the database. Prior to 2013, all patients fulﬁlled either
the American College of Rheumatology (ACR) or Leroy and
Medsger criteria for SSc,[11,12] while post 2013 all patients were
reclassiﬁed according to the 2013 ACR/EULAR classiﬁcation
criteria.[13]
2.2. Healthcare utilization
Healthcare utilization in Victoria was captured by means of data
linkage. Through the Australian Institute of Health and Welfare,
the ASCS database of deidentiﬁed SSc patients’ demographic
information, disease-related data, medication, and patient
reported outcome measure data were merged with the Victorian
Admitted Episodes Dataset, the Victorian Emergency Minimum
Dataset, and the MBS, thereby capturing all hospital admissions,
ED presentations, and ambulatory care use. All merged data were
deidentiﬁed prior to being stored and analyzed within the Secure
Uniﬁed Research Environment, which is a remote-access secure
computing environment that allows researchers to analyze linked
data. As the Australian administrative databases are not linked
across the country, completing a nationwide data linkage
approach across states other than Victoria was not feasible.
2.3. Hospitalization and ED presentation data
The Victorian Admitted Episodes Dataset contains information
on the primary diagnosis and/or procedure for patients admitted
to hospital, their length of stay (LOS), hours in the intensive care
unit and/or coronary care unit, and the diagnosis related group
(DRG) for each admission. The Victorian Emergency Minimum
Dataset contains information on the primary diagnosis and/or
procedure for ED presentation, the triage category, and departure
destination.
We divided our admitted and ED presentation patients into
groups: low and high number of admissions; ED presentations;
and LOS, based on the median number of admissions, ED
presentations, and LOS, respectively, for the whole group. We
then compared demographics and disease-related data in the low
versus high groups.
2.4. Ambulatory care data
The MBS lists the professional services for which a government-
funded payment can be claimed[14] and includes GP visits,
physician and surgical visits, and allied health visits, together
with pathology and imaging, performed within Australia. Every
MBS-listed service is assigned a “schedule fee,” an amount the
government considers appropriate for the service and a “beneﬁt
payable fee,” that is approximately 75% to 85% of the schedule
fee which the government contributes. Some practitioners’ fees
are above the beneﬁt payable fee meaning that patients pay an
“out of pocket fee” that is not redeemable from the government.
This out of pocket fee was not calculated in this paper.
Furthermore, any services not covered by the MBS that patients
utilize and self-fund, such as osteopathy, were not captured.
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The MBS does not cover public hospital outpatient clinics. To
avoid underestimating ambulatory care utilization, we also
estimated the outpatient clinic cost of SSc patients enrolled in
ASCS at St Vincent’s Hospital Melbourne by quantifying use and
associated costs in collaboration with the decision support unit at
the hospital. At Monash Health, all rheumatology outpatient
visits are “privately” billed, and hence use and associated cost are
captured in the MBS database.
2.5. Medication data
Medication utilization and duration of use was determined from
the ASCS database, wherein detailed medication use data are
recorded at each visit for all patients enrolled. Although the
Australian government PBS database records medications
dispensed to individuals covered by Medicare, only medications
with costs above a threshold of Australian Dollar (AUD)$38.80
are recorded in this administrative database. Furthermore, ethical
approval is not granted by the data custodians for linkage with
both the PBS and MBS databases due to concerns regarding
potential patient reidentiﬁcation with merging of multiple
datasets.
2.6. Costing methodology
2.6.1. Hospital cost. In the Australian public hospital system,
every admission is allocated a DRG, based on the International
Classiﬁcation of Diseases (ICD) and a weighted inlier equivalent
separation (WIES) based on the primary reason for admission,
DRG, complications, LOS, and individual patient factors. The
WIES value incorporates the cost of investigations and
medications administered for that condition in a hospital setting.
Cost was calculated based on ﬁnancial year of admission and the
corresponding WIES for that ﬁnancial year. A sensitivity analysis
of hospitalization related cost was performed based on estimated
private hospitalizations in the same period (40%) on the premise
that the patient complexity was the same between public and
private admissions.[9]
Victorian ED presentations are “block funded,” meaning that
each hospital receives an annual amount of money that is
calculated based on anticipated ED presentations and cost of staff
required to maintain ED cubicles and patient care. For the
purpose of this paper, the average cost of an ED presentation
during this time period (2011–2015) was calculated for each of
the 2 participating Victorian hospitals (AUD$689.57 for St
Vincent’s Hospital and AUD$590.00 for Monash Health).
2.6.2. Ambulatory care cost. Ambulatory care cost was
calculated using the total MBS “beneﬁt payable fee” as this is
what the government contributed toward each service, making it
an accurate reﬂection of the direct cost and hence economic
burden to the Australian government.
2.6.3. Medication cost. Medication cost was determined from
the PBS dispensed price for maximum quantity (DPMQ) paid for
the standard dose of each medication. The DPMQ is the cost the
government contributes toward each medication dispensed, thus
making the medical cost an accurate reﬂection of the direct cost to
the Australian government. Average duration on eachmedication
was calculated and the cost of a standard dose of each medication
to the government was estimated. All medications with a PBS
listing were included in the calculation of total medication cost,
with only complementary and over the counter medications
excluded.
2.7. Extrapolation of cost to all Australian SSc patients
The proportion of SSc patients recruited in the ASCS was
estimated relative to the prevalence of SSc in Australia (21.1 per
100,000)[15,16] and population data from the Australian Bureau
of Statistics (Victorian population of 5,996,400, Australian
population of 24,304,682 in 2015).[10] Extrapolation of total
cost to the Australian government was based on the estimated
number of SSc patients in Victoria (n=1266) and in Australia
(n=5129).[15,16] Costs are also presented in US dollars (USD)
based on currency conversion performed on 10th May 2017.
2.8. Clinical data
Patient demographics and clinical variables were obtained from
the ASCS database. Prior to the ASCS clinical patient data
linkage, any missing patient data including disease manifes-
tations, medication utilization, and patient status were retrieved
from the treating clinician and recorded before the linkage
occurred. As patient data are collected in the ASCS on an annual
basis, patients were classiﬁed as lost-to-follow-up if they had been
uncontactable for a period of 18 months. The period of 18
months was selected to allow for delays in data entry. There were
2 patients out of 531 Victorian SSc patients lost-to-follow-up
included in this data linkage study. Clinical manifestations and
autoantibody status were deﬁned as present if present ever from
the time of diagnosis of SSc. Extent of skin involvement was
determined using the modiﬁed Rodnan skin scores (mRSS).
Physician classiﬁcation of patients into lcSSc and dcSSc was
conﬁrmed by reviewing recorded mRSS scores. lcSSc was deﬁned
as skin involvement distal to the elbows and knees with or
without facial involvement; dcSSc was deﬁned as skin involve-
ment proximal to the elbows and knees, with or without truncal
involvement. Pulmonary arterial hypertension (PAH) was
diagnosed on right heart catheterization (RHC) according to
international criteria.[17] Interstitial lung disease was deﬁned
based on characteristic changes on high-resolution computer
tomography lung. Renal crisis was deﬁned as a combination of
any 2 of the following criteria: new onset severe hypertension
without an alternate etiology; microangiopathic hemolytic
anemia; and rising creatinine. Upper gastrointestinal (GIT)
involvement included the presence of reﬂux esophagitis and/or
esophageal stricture on endoscopy. Lower GIT involvement
included the presence of bowel dysmotility deﬁned on barium and
nuclear medicine studies, antibiotic response and/or characteris-
tic symptoms, and fecal incontinence. GIT involvement included
the presence of both upper and lower GIT involvement. Hand
dysfunction was deﬁned based on the presence of joint
contractures and/or deformities.
Global disease activity and severity were measured using
physician-rated scales ranging from 0 to 10, with 0 being no
activity or severity and 10 being very severe activity or
severity.[18]
2.9. Statistical analysis
Data are presented as mean± standard deviation for normally
distributed and median (interquartile range [IQR]) for non-
normally distributed continuous variables, and as number
(percentage) for categorical variables. Differences in frequency
were tested using chi-square and Fisher exact tests. Univariable
and multivariable logistic regression were used to determine the
associations of different factors with healthcare utilization and
cost. A 2-tailed P value of.05 or less was considered statistically
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signiﬁcant. All statistical analyses were performed using STATA
14.0 (StataCorp LP, College Station, TX).
3. Results
3.1. Hospitalizations
Of the 531 Victorian SSc patients enrolled in ASCS between
January 2011 and December 2015, 432 patients (81.4%) were
admitted to hospital at least once. The total number of hospital
admissions during this period was 3948, equating to an average
of 789.9 admissions annually. The median (IQR) number of
hospitalizations per patient per year was 5 (2–11) with a median
LOS of 1 day (1–2.5). There was no difference in admission
frequency among the seasons or months of the year. Of the
admitted patients, 70 (16.2%) patients spent time in the intensive
care unit (medianhours 47 [25–124]) and 42 (9.7%) spent time in
the coronary care unit (medianhours 31 [6–59.5]).
The majority of admissions were acute care (96.9%), followed
by rehabilitation (0.9%), palliative care (0.7%), geriatric (0.7%),
and acute mental health service (0.7%).
Patient characteristics by admission status are summarized in
Table 1. Factors associated with hospital admission in univari-
able and multivariable logistic regression analysis are summa-
rized in Supplementary Table 1, http://links.lww.com/MD/B986,
while factors associated with above average number of hospital
admissions and LOS, determined using univariable and multi-
variable logistic regression analysis, are shown in Supplementary
Tables 2 and 3, http://links.lww.com/MD/B986.
The most common principal diagnoses for hospital admissions
in SSc patients hospitalized between 2011 and 2015 are
summarized in Supplementary Table 4, http://links.lww.com/
MD/B986. Disorders of the digestive system accounted for the
majority of major admission categories (21.8%), followed by
disorders of the musculoskeletal system (MSK) and connective
tissue accounting for 21.3% of admissions (Supplementary
Table 5, http://links.lww.com/MD/B986).
3.2. Hospital admission cost
The cost associated with inpatient hospitalization during 2011 to
2015 for Victorian SSc patients within ASCS amounted to AUD
$12,734,394.95 (USD$9,372,514.68) (annual cost of AUD
$2,546,878.99 [USD$ 1,874,502.94]). The median hospitaliza-
tion cost per patient over the 5-year period was AUD$16,144.5
(IQR 5,963.16–43,754.14 [USD$11,882.35, IQR 4388.89–
32,203.05]), amounting to an annual per patient median cost
of AUD$3228.9 (USD$2376.47).
Factors associated with above median hospitalization costs,
determined using univariable logistic regression analysis, are
summarized in Supplementary Table 6, http://links.lww.com/
MD/B986. Factors associated with above median hospitalization
costs, determined using multivariable logistic regression analysis,
included PAH (OR 2.3, P= .01), digital amputation (OR 4.1,
P= .01), longer SSc disease duration (OR 1.0, P= .02), renal crisis
(OR 3.2, P= .04), upper GIT involvement (OR 1.8, P= .01), and
coexistent diabetes mellitus (OR 3.6 P< .001) (Table 2).
3.3. Emergency department presentations
Of the 531 Victorian SSc patients enrolled in ASCS between
January 2011 and December 2015, 293 patients (55.2%)
presented to the ED at least once. The total number of ED
presentations during this period was 1455 (1090 to St Vincent’s
Hospital and 365 toMonash Health, Melbourne), equating to an
average of 291 presentations per year. The median number of ED
presentations per patient per year was 3 (IQR 1–5) with no
difference among the seasons or months of the year.
Of those patients who presented to the ED, all presentations
were emergency presentations (99.7%) except for one patient
who had a planned return to the ED. Patient characteristics by ED
presentation are summarized in Table 1. Factors associated with
ED presentation, determined using univariable, and multivari-
able logistic regression analysis, are shown in Supplementary
Table 1, http://links.lww.com/MD/B986. Factors associated with
above median annual number of ED presentations (n=3) in SSc,
determined using univariable logistic regression analysis are
shown in Supplementary Table 2, http://links.lww.com/MD/
B986. Factors associated with above median annual number of
ED presentations in SSc, determined using multivariable logistic
regression analysis, included the presence of digital ulcers (OR
1.7, P= .01), lower 6-minute walk distance (OR 0.9, P= .01), and
coexistent diabetes mellitus (OR 2.9, P= .02) (Table 2).
The most common principal diagnoses for ED presentations in
SSc patients are summarized in Supplementary Table 4, http://
links.lww.com/MD/B986. Chest pain (5.9%) was the most
common principal diagnosis for ED presentation followed by
abdominal pain (3.5%).
3.4. ED presentation cost
The cost associated with ED presentations during 2011 to 2015
for SSc patients within ASCS amounted to AUD$961,671.30
(USD$707,789.87) (average annual cost AUD$192,334.26 [USD
$141,557.97]). No sensitivity analysis was performed to account
for ED presentations to private hospitals, as over 94% of ED
presentations in Australia occur in public hospitals.
3.5. Total hospital costs
Total hospital cost, including hospitalization and ED costs, for all
Victorian SSc patients between 2011 and 2015 amounted to
AUD$32,653,898.06 (USD$ 24,033,268.47) (average annual
cost of AUD$6,530,779.61, USD$4,806,653.69). For all Aus-
tralian SSc patients, this would amount to AUD$132,292,135.17
(USD$97,376,009.45) (average annual cost of AUD
$26,458,427.04, USD$19,473,401.90), with an annual cost
per patient of AUD$5158.59 (USD$3796.72).
Assuming that public hospital use accounted for only 60%
of all hospital use, total hospital costs extrapolated to all
Australian SSc patients over the 5 year period would be AUD
$220,486,891.80 (USD$162,278,303.97), with an average
annual cost of AUD$44,097,378.39 (USD$32,455,660.79)
and an annual cost per patient of AUD$8597.66 (USD
$6327.87).
3.6. Ambulatory care utilization
Of the 531 Victorian SSc patients enrolled in the ASCS between
2011 and 2015, 494 (93.0%) utilized an ambulatory care
service reimbursed through the MBS. Patient characteristics are
summarized in Table 1.
The majority of ambulatory care cost for ASCS SSc patients
was for professional attendances (MBS category 1 services)
totaling AUD$2,649,682.35 between 2011 and 2015. Diagnostic
procedures (MBS category 5), encompassing the use of ultra-
sound, echocardiography, computer tomography, magnetic
resonance imaging, and nuclear medicine, comprised the 2nd
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most costly service category, totaling AUD$1,386,737.90,
followed closely by pathology services (MBS category 6) totaling
AUD$1,070,187.00 and therapeutic procedures (MBS category
3) totaling AUD$926,009.25. Table 3 summarizes all MBS
services provided, their associated frequency of use and costs.
Between 2011 and 2015, allied health services (MBS category
8) accounted for the 6th most expensive MBS service for ASCS
SSc patients at AUD$344,829.65. Podiatry was the most
frequently used and costly service accounting for 8.9% of all
allied health services and AUD$93,649.80, followed by psycho-
logical therapy (3.2%, AUD$61,781.45).
3.7. MBS-related ambulatory cost
The total MBS cost of ambulatory care for Victorian ASCS SSc
patients over this 5-year period was AUD$6,993,367.19 (USD
$5,147,118.25) (average annual cost of AUD$1,398,673.44
(USD$1,029,423.65), annual per patient cost of AUD$2831.32
[USD$2083.85]).
3.8. Determinants of ambulatory care cost
Patient characteristics based on the median total ambulatory care
cost (AUD$11,778.23) are shown in Supplementary Table 7,
http://links.lww.com/MD/B986. Patient factors associated with
above median ambulatory care costs, determined using univari-
able logistic regression analysis, are presented in Supplementary
Table 6, http://links.lww.com/MD/B986. Factors associated with
above the median ambulatory care costs, determined using
multivariable logistic regression analysis, included age over 60
years at SSc onset (OR 2.8, P= < .001), longer SSc disease
duration (OR 1.0, P= .01), PAH (OR 2.8, P= .01), GIT
involvement (OR 2.0, P< .001), synovitis (OR 2.0, P= .01),
and coexistent diabetes mellitus (OR 2.7 P= .02) (Table 2).
3.1. Public hospital outpatient clinic cost for SSc patients
Over the same 5-year period as described above, 263 Victorian
SSc patients enrolled in the ASCS attended the outpatient clinic at
St Vincent’s Hospital, a large tertiary public hospital in
Melbourne, Victoria. Patient characteristics were similar to the
MBS merged dataset and are described in Table 1. Outpatient
clinic attendance and associated costs are outlined in Table 4.
The total cost for St Vincent’s hospital outpatient clinic over
this 5-year period was AUD$1,495,042.72 (USD$1,100,351.44)
(annual cost of AUD$299,008.54 (USD$220,070.29), annual
per patient cost of AUD$1136.92 [USD$836.77]). This cost
encompassedmedical, surgical, and allied health costs in addition
to pathology and imaging costs. As mentioned above, rheuma-
tology outpatient clinics at Monash Health are privatized and
their cost is captured in theMBS cost. Therefore, outpatient clinic
cost has not been extrapolated to all Victorian or Australian SSc
patients due to the potential for over-estimation.
3.2. Medication utilization
Medications were categorized by their clinical indication and SSc
disease manifestations as shown in Table 5. From 2011 to 2015,
the total medication cost in Victorian SSc patients was AUD
$9,603,557.77 (USD$7,068,218.52) with an annual cost per
patient of AUD$3617.16 (USD$2662.23).
PAH speciﬁc therapies accounted for the highest medication-
related cost (AUD$7, 238,823.76, USD$5,327,774.29),
despite only 10.7% of patients in the cohort having PAH. The
annual medication cost per PAH patient was AUD$21,290.66
(USD$15,669.93). Immunosuppressive therapies were the 2nd
most costly medication class accounting for a cost of AUD
$1,062,216.45 (USD$781,791.31) between 2011 and 2015
(average annual cost of AUD$212,443.29, USD$156,358.26).
3.3. Determinants of medication cost
Patient characteristics by median medication cost for the cohort
(AUD$2858.369) are shown in Supplementary Table 7, http://
links.lww.com/MD/B986. Factors associated with above median
medication costs in univariable logistic regression analysis are
presented in Supplementary Table 6, http://links.lww.com/MD/
B986. Factors associated with above median medication cost,
determined using multivariable logistic regression analysis,
included dcSSc (OR 2.1, P= .01), PAH (OR 7.8, P< .001),
interstitial lung disease (OR 1.9, P< .001), GIT manifestations
(OR 1.6, P= .03), synovitis (OR 1.8, P= .01), and higher SSc
disease activity score (OR 1.2, P= .01) (Table 2).
3.4. Total health care cost to the Australian government
Extrapolating total health care cost from 2011 to 2015 to all
Australian SSc patients would equal AUD$297,663,404.77 (USD
Table 2
Independent determinants of above median health care cost
∗
by
multivariable logistic regression analysis.
Hospital cost (n=428)
Patient characteristic OR (95%CI) P
SSc disease duration† 1.03 (1.0–1.1) .02
Renal crisis‡ 3.23 (1.1–9.8) .04
PAH‡ 2.28 (1.2–2.8) .01
Digital amputation‡ 4.10 (1.6–7.9) .01
Upper GIT involvement‡ 1.83 (1.2–2.8) .01
Diabetes mellitus‡ 3.62 (1.7–7.9) <.001
Ambulatory care cost (n=494)
Patient characteristic OR (95%CI) P
Age >60 years at onset of SSc† 2.8 (1.6–5.1) <.001
SSc disease durationx 1.0 (1.0–1.1) .01
PAH‡ 2.8 (1.4–5.7) .01
GIT manifestations‡ 2.0 (1.3–3.1) <.001
Synovitis‡ 2.0 (1.3–3.2) .01
Diabetes mellitus 2.7 (1.2–6.3) .02
Medication cost (n=531)
OR (95%CI) P
Age at SSc diagnosis† 0.9 (0.9–1.0) .56
SSc disease durationx 1.0 (0.9–1.0) .23
Female 1.4 (0.8–2.6) .32
Diffuse disease subtype 2.1 (1.3–3.6) .01
PAH‡ 7.8 (3.4–18.3) <.001
ILD‡ 1.9 (1.2–2.9) <.001
GIT manifestations‡ 1.6 (1.1–2.5) .03
Synovitis‡ 1.8 (1.2–2.9) .01
EUSTAR disease activity index 1.2 (1.1–1.4) .01
ASCS=Australian Scleroderma Cohort Study, AUD=Australian Dollar, CI= conﬁdence interval, GI=
gastrointestinal, GIT=gastrointestinal, IHD= ischemic heart disease, ILD= interstitial lung disease,
6MWD=6-minute walk distance, OR= odds ratio, PAH=pulmonary arterial hypertension, SSc=
systemic sclerosis.
∗
Median cost for hospital cost for the Victorian cohort of ASCS patients (AUD$16,144.50), median
ambulatory care cost (AUD$11,778.23), and median medication cost (AUD$2858.37).
† Age in years at SSc onset deﬁned as age at 1st SSc clinical manifestation.
‡Manifestations are deﬁned as present if ever present from SSc diagnosis.
x Disease duration in years at 2015.
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Table 3
Frequency and cost of MBS services provided between 2011 and 2015 (“beneﬁts paid”).




Category 1: professional attendances
GP visits† comprised of: 26,388 (60.8%) $1,368,644.4 $1,502,013.95
Routine visit 22,835 (52.6%) $994,009.0 $1,117,520.5
GP management plans 1942 (4.5%) $228,770.9 $232,211.4
After hours 1144 (2.6%) $88,394.15 $94,208.85
Mental health treatment 314 (0.7%) $27,759.9 $28,298.4
Health assessment 117 (0.3%) $24,595.05 $24,659.4
Domiciliary and residential reviews 36 (0.1%) $5115.4 $5115.4
Consultant physician attendance 10,761 (24.9%) $935,755.1 $1,224,175.20
Specialist attendance (surgical) 3122 (7.2%) $161,525.4 $271,891.9
Consultant psychiatrist attendance 598 (1.4%) $82,818.7 $105,152.8
Optometrical services 1357 (3.1%) $64,797.0 $65,400.4
Acupuncture 344 (0.8%) $21,877.15 $23,492.2
Neurosurgery attendance 59 (0.1%) $5395.2 $9042.25
Pain and palliative medicine 43 (0.1%) $3470.4 $4922.4
Emergency physician attendance 22 (0.1%) $3194.1 $4801.85
Geriatric medicine 3 (0.01%) $1324.6 $1324.6
Group therapy 4 (0.01%) $450.25 $450.25
Telehealth with GP or physician 5 (0.01%) $430.05 $430.05
Total cost for category 1 42706 (100%) $2,649,682.35 $3,213,097.85
Category 2: diagnostic procedures
Respiratory 2166 (55.6%) $246,209.7 $248,729.8
Ophthalmology 137 (3.5%) $59,387.45 $113334.9
Cardiovascular 986 (25.3%) $47,803.65 $53,071.42
Other 306 (7.9%) $33,107.35 $37,636.0
Gastroenterology and colorectal 47 (1.2%) $19,681.1 $20,908.7
Neurology 55 (1.4%) $9905.1 $12,662.85
Otolaryngology 97 (2.5%) $3756.25 $4209.65
Genitourinary physiological investigations 7 (0.2%) $1859.8 $2560.9
Allergy testing 14 (0.4%) $610.5 $614.45
Total cost for category 2 3898 (100%) $422,320.9 $493,728.67
Category 3: therapeutic procedures
Surgical operation 2103 (36.6%) $455,965.1 $845,243.1
Anesthetics 1748 (30.5%) $170,624.8 $370,474.7
Radiation oncology 289 (5.0%) $46,323.35 $47,494.2
Operation assistance 127 (2.2%) $22,470.35 $43,721.09
Obstetrics 82 (1.4%) $7795.85 $22,008.0
Regional nerve block 53 (0.9%) $5523.7 $7668.45
Botulinum toxin injection 21 (0.4%) $4053.0 $4524.5
Therapeutic nuclear medicine 11 (0.02%) $284.6 $284.6
Other therapeutic procedure 1315 (22.9%) $212,968.5 $323,583.1
Total cost for category 3 5739 (100%) $926,009.25 $1,665,001.74
Category 4: oral and maxillofacial services
Consultations 11 (100%) $880.75 $1218.95
Total cost for category 4 11 (100%) $880.75 $1218.95
Category 5: diagnostic imaging
Ultrasound 3757 (44.9%) $649,986.1 $696,359.7
Computed Tomography 959 (11.5%) $295,416.9 $329,353.1
Diagnostic radiology 3009 (35.9%) $213,668.2 $272,559.9
Magnetic resonance imaging 385 (4.6%) $118,358.1 $127,613.9
Nuclear medicine 246 (2.9%) $109,308.6 116,006.5
Total cost for category 5 8365 (100%) $1,386,737.9 $1,541,893.1
Category 6: pathology services
Pathology 75734 (100%) $1,070,187.0 $1,199,260.0
Total cost for category 6 75734 (100%) $1,070,187.0 $1,199,260.0
Category 7: cleft lip/palate services 0 0 0
Category 8: allied health services
Podiatry 1780 (8.9%) $93,649.8 $98,732.55
Psychology/mental health service 639 (3.2%) $61,781.45 $77,862.2
Physiotherapy 604 (3.0%) $31,972.1 $35,601.55
Chiropractor 107 (0.5%) $5572.0 $5727.85
Nurse practitioner 19 (0.1%) $4435.0 $4441.5
Osteopathy 74 (0.4%) $3900.3 $4381.6
Occupational therapy 66 (0.3%) $3462.75 $3536.05
Dietician 62 (0.3%) $3369.5 $4211.15
Allied health services for chronic disease 8 (0.04%) $501.0 $646.8
Diabetic educator 9 (0.1%) $381.5 $395.6
Audiology services 5 (0.03%) $126.65 $157.65
(continued )
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$219,080,200.42) (annual cost AUD$59,532,680.95, USD
$43,816,040.08), with an annual cost per patient of AUD
$11,607.07 (USD$8542.80). Hospital costs accounted for the
majority of these costs (44.4% of total annual cost, AUD
$26,458,427.04, USD$19,473,401.90), followed by medication
cost (31.2%, AUD$18,552,413.60, USD$13,654,576.41), and
ambulatory care cost (24.4%, AUD$14,521,840.30 (USD
$10,688,074.46) (Table 6).
4. Discussion
Our study demonstrates that despite SSc being a low prevalence
condition, it is associated with substantial healthcare utilization
and cost. In our Victorian SSc cohort, over 80% (81.4%) were
admitted to hospital at least once between 2011 and 2015,
totaling 3948 hospital admissions with an overall cost of AUD
$12,734,394.95 (USD$9,372,514.68); over half (55.2%) pre-
sented to the ED on at least 1 occasion, totaling 1455
presentations with an associated cost of AUD$192,334.26
(USD$141,557.97) and 93.0% utilized an ambulatory care
service reimbursed through the MBS AUD$17,922,255.60 (USD
$13,190,780.12). Using SSc prevalence data, the total health
care expenditure extrapolated to all Australian SSc patients
during this time period was AUD$297,663,404.77.15 (USD
$219,080,200.42) (annual cost AUD$59,532,680.95, USD
$43,816,040.08) with an annual cost per patient of AUD
$11,607.07 (USD$8542.80).
MSK conditions are increasingly recognized as a signiﬁcant
contributor to the global burden of disease (GBD) constituting
the 2nd most common cause of disability worldwide.[19] In
Australia, arthritis andMSK conditions (including osteoarthritis,
RA, back problems, and “other” MSK conditions such as SSc)
constitute the 4th highest healthcare expenditure in 2008 to 2009
consuming 8.7% of the AUD$65,129 million healthcare
expenditure allocated to disease groups.[20] The ﬁnancial
healthcare burden including hospital admitted patient services,
out-of-hospital medical services, and prescription medications
associated with MSK conditions in Australia was AUD$1637
million for osteoarthritis, AUD$1177 million for back problems,
AUD$44 million for RA, and AUD$44 million for osteoporo-
sis.[20] There have been no previous studies assessing the cost of
SSc in Australia, but based on our results, the annual cost of SSc
(AUD$59 million) is more than some other MSK disorders with
higher prevalence, for example, osteoporosis.[20]
Table 3
(continued).




Telehealth for allied health 1 (0.1%) $32.4 $32.4
Other bulk billed services $135,645.20 $135,786.70
Total cost for category 8 19824 (100%) $344,829.65 $371,513.6
Category 9: dental services
Dental services 157 (100%) $43,204.8 $48,704.1
Total cost for category 9 157 (100%) $43,204.8 $48,704.1
Unknown services $149,514.59 $113,133.89
Total Cost all categories AUD$ $6,993,367.19 $8,647,551.90
Annual cost all categories AUD$ $1,398,673.44 $1,729,510.38
GP=general practitioner, MBS=Medicare Beneﬁts Schedule.
∗
Every MBS-listed service is assigned a “schedule fee,” an amount the government considers appropriate for the service and a “beneﬁt payable fee” that is approximately 75% to 85% of the schedule fee and
which the government contributes (government cost). We used the beneﬁt payable fee to estimate total ambulatory care cost to the government.
† In Australia, the GP is the primary care provider to all patients. Visits to GPs are varied with “routine visits” compromising a patient visiting the GP ofﬁce during working hours; “after hours” refers to a visit outside
of working hours; a “GP management plan,” a “mental health treatment,” and a “health assessment” is a longer visit that a GP can provide for a more complex patients or those with mental health concerns to
ensure a thorough and multidisciplinary team approach to patient care; and a “domiciliary and residential reviews” is when a GP visits a patients home or a nursing home to provide medical assistance to that
person.
Table 4
Public tertiary hospital outpatient clinic costs associated with SSc
patients.
Clinic variables Cost (AUD$) or n, %
Patient number 263
Total outpatient clinic cost $1,495,042.72
Consisting of
Medical specialist cost $577,669.51
Pharmacy costs $438,989.52
Pathology cost $156,360.83
Allied health cost $130,971.42
Imaging costs $87,299.18
Nursing cost $73,018.17
Surgical specialist cost $30,734.12










Chronic pain clinic 25 (0.9%)
Endocrinology 22 (0.8%)
General medicine clinic 19 (0.7%)
Surgical specialist clinic visits 375 (9.3%)
Consisting of
Vascular clinic 99 (26.4%
Plastic clinic 83 (22.1%)
Orthopedic clinic 53 (14.1%)
Colorectal/hepatobiliary clinic 69 (18.4%)
Breast clinic 26 (6.9%)
ENT 5 (1.3%)
Cardiothoracics 1 (0.3%)





Hand therapy 123 (14.5%)
Prosthetics and orthotics 120 (14.2%)
Social work 16 (1.9%)
Speech pathology 8 (0.9%)
AUD=Australian Dollar, SSc= systemic sclerosis.
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SSc-speciﬁc healthcare-related costs vary geographically and
depending on what is included in the cost estimation (hospitali-
zation, ambulatory care, and/or medication cost). Within
Australia, for example, access to certain emerging treatment
opportunities for the treatment of SSc, such as autologous stem
cell transplantation in SSc,[21,22] is not equitable between all
Australian States being currently only available at 1 tertiary
institution in New South Wales (NSW). Consequently, the costs
of SSc in Victoria may vary from that in NSW. Our estimated
direct cost per SSc patient per annum is AUD$11,607.07 (USD
Table 5














PAH speciﬁc therapy (PAH patients n=68) n (%), (% with PAH) $7,238,823.76
Bosentan 47 (8.9%) (69.1%) 3.8±2.8 5,856,615.48
Sitaxentantan 0 (0%) 1.6±1.1 0
Ambrisentan 14 (2.6%) (20.5%) 2.4±1.7 1,101,804.48
Macitentan 4 (0.8%) (5.9%) 0.3±0.6 42,098.26
Inhaled Iloprost 2 (0.4%) (0.1%) 2.3±2.6 3,761.70
Sildenaﬁl 26 (4.9%) (38.2%) 1.7±1.9 169,579.49
Tadalaﬁl 4 (0.8%) 5.9%) 1.6±0.9 64,164.86
Intravenous epoprostenol 1 (0.2%) (1.5%) 0.9±0.0 799.50
Immunosuppressive therapy $1,062,216.45
DMARDs $816,937.97
Prednisolone 158 (29.8%) 4.2±2.9 35,993.66
Leﬂunomide 2 (0.4%) 3.6±5.1 3,141.50
Methotrexate 77 (14.5%) 4.3±2.8 180,065.42
Azathioprine 41 (7.7%) 4.6±2.7 70,770.26
Penicillamine 8 (1.5%) 5.0±3.7 8131.20
Hydrochloroquine 70 (13.2%) 3.8±2.6 28,206.64
Mycophenolate mofetil 60 (11.3%) 3.5±2.7 411,717.60
Cyclophosphamide 21 (3.9%) 0.5±0.2 3508.47
Cyclosporin 5 (0.9%) 2.3±3.5 75,403.20
Biological agents 3 (0.6%) 3.9±2.0 $245,278.48
TNF inhibitor 1 (0.2%) 2.0 196,742.52
Rituximab 1 (0.2%) 1.0 24,527.92
Tocilizumab 1 (0.2%) 1.1 11,432.40
Abatacept 12,575.64
Gastrointestinal medications $778,992.40
Proton pump inhibitor 479 (90.2%) 4.4±2.7 737,997.22
Histamine-2-receptor antagonist 103 (19.4%) 3.3±2.9 10,618.48
Promotility agent 54 (10.2%) 3.2±2.4 26,127.36
Cyclical antibiotics 22 (4.1%) 3.2±3.2 4249.34
Parenteral Nutrition (IV TPN) 25 (4.7%) N/A N/A
Cardiovascular medications $271,888.33
ACE inhibitor 134 (25.2%) 4.5±2.8 103,185.36
Angiotensin receptor antagonist 106 (19.9%) 3.8±2.8 58,003.20
Diuretic therapy 119 (22.4%) 3.8±2.8 83,626.99
Beta-blocker therapy 11 (2.1%) 1.2±0.6 657.89
Antiarrhythmic agent 35 (6.6%) 2.9±2.5 4275.18
Lipid lowering therapy 157 (29.6%) 3.6±2.3 83,626.99
Raynaud’s/DU treatment $187,550.48
Calcium channel blocker 315 (59.3%) 4.5±2.7 142,033.50
Topical vasodilator 16 (3.0%) 3.7±2.3 N/A
Prostaglandins/Iloprost 27 (5.1%) 3.9±2.5 45,516.98
Antiplatelet agents/Anticoagulants $64,086.35
Aspirin 142 (26.7%) 3.8±2.7 26,764.16
NSAIDS 80 (15.1%) 4.5±2.5 25,099.20
Warfarin 39 (7.3%) 3.1±2.6 12,222.99
Opioid therapy 11 (2.1%) 0.9±0.8 179.289
Total cost for the cohort 2011–2015 AUD$ 9,603,557.77
Total average annual cost for the cohort AUD$ 1,920,711.55
ACE= angiotensin converting enzyme, AUD= australian Dollar, DMARD=disease modifying anti-rheumatic drugs, DU=digital ulceration, N/A=not available, NSAIDs=non steroidal anti-inﬂammatory drugs,
PAH=pulmonary arterial hypertension, PBS=pharmaceutical beneﬁts scheme, SSc= systemic sclerosis, TNF= tumour necrosis factor, TPN= total parenteral nutrition.
∗
Standard dose of each medication which was used for cost calculation include: PAH therapy dose is as per the PAH treatment guidelines, prednisolone 5mg, leﬂunomide 10mg, methotrexate 10mg,
azathioprine 50mg, penicillamine 125mg, hydrochloroquine 200mg, mycophenolate mofetil 1 g, cyclophosphamide (for 6 cycles), cyclosporin 50mg, proton pump inhibitor 20mg, histamine-2-receptor
antagonist (ranitidine 150mg), promotility agent (domperidone 10mg), ace inhibitor (perindopril 5mg), angiotensin receptor antagonist (irbesartan 150mg), diuretic (frusemide 20mg), beta-blocker (metoprolol
50mg), antiarrhythmic (digoxin 62.5mcg), lipid lowering therapy (simvastatin 10mg), calcium channel blocker (nifedipine 10mg), aspirin 100mg, and opioid (endone 5mg).
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$8542.80), which is remarkably similar to estimate worldwide.
For example, the annual direct per patient cost of SSc in Canada is
estimated to be CAD$5038,[5] in the US to range between USD
$8441 and $17,365,[23,24] in Spain to be €8235,[7] in France to be
€8452,[6] in Hungry to be €4232,[3] and in Europe to range
between €1413 and 17,300.[8] In our study, hospital related cost
accounted for the majority of the total direct healthcare cost
(44.4%), followed by medication cost (31.2%) and ambulatory
care cost (21.1%). Our healthcare costs in SSc are consistent with
other countries such as Canada where hospital cost accounted for
34.9% while medication cost accounted for 31.2% of direct cost
in SSc patients,[5] and in America were ambulatory care
accounted for 19% of the total healthcare cost incurred by
SSc patients.[25]
Utilization of ambulatory care, particularly allied health
services, among Australian SSc patients was very common in
our study and is mirrored in other countries such as the
Netherlands where 61% of the SSc cohort had utilized allied
health services within the last year most commonly physiothera-
py, and averaged 7.5 visits annually to an allied health
provider.[26,27] These results reinforce the importance of a
multidisciplinary team approach to SSc management and
highlight the need for consistent government funding to ensure
these services remain accessible to all SSc patients regardless of
their socioeconomic background.
SSc-PAH contributes to signiﬁcant morbidity, mortality, and
poor health-related quality of life compared with SSc patients
without PAH.[28–30] Our study shows that that the presence of
SSc-PAH is associated with a higher frequency of inpatient
hospitalization, longer LOS, and higher hospital costs, in
addition to a higher frequency of ambulatory service utilization
and associated cost. Furthermore, despite only 10.7% of patients
having SSc-PAH in our study, PAH speciﬁc therapy accounted for
the majority (75.4%) of the total medication-related cost. This
highlights the signiﬁcant and concerning burden associated with
SSc-PAH impacting not only patients but also the wider society
through healthcare utilization and associated cost. Further
research in this area is required to enable effective intervention
to modify this burden.
Diabetes mellitus (DM) affects over 1 million Australians and
is associated with a signiﬁcant direct healthcare cost,[31] which is
why we think that the coexistence of DM was an independent
determinant of healthcare costs in SSc patients.
We expect our ﬁndings to be generalizable to other developed
countries with a similar healthcare system. Our results highlight
that “other” MSK conditions such as SSc are not only an
important contributor to the burden of disease but are also a
central component of health expenditure in many high-income
and middle-income countries.[20,32]
Strengths of our study include the large, well-deﬁned
multicenter cohort of patients with conﬁrmed SSc, and detailed
patient-related data recorded systematically using well-validated
tools and methods. Furthermore, our healthcare cost is a true
reﬂection of the government cost derived from the MBS beneﬁt
paid and PBS DPMQprice. This study was performed to quantify
the direct healthcare costs of Australian SSc patients. We did not
evaluate the economic implications of treating certain disease
manifestations such as PAH and/or GIT manifestations. We do
note the importance of such economic studies and recommend
this as an area of further research. Limitations include the
possibility of underestimating the true cost associated with
hospitalizations due to geographic variation across Australian
States, which may impact on treatment opportunities (such as
ASCT). We were also unable to determine if there was a
relationship between the geographic region and healthcare
utilization due to ethical restrictions with potentially reidentify-
ing variables such as patients’ and/or hospitals’ geographic
postcode. Additionally, hospitalizations in the private sector
which were not included, although we attempted to estimate the
additional private sector hospitalization costs in our sensitivity
analyses. Furthermore, we did not include the cost of public
outpatient clinics, any privately funded allied health service not
covered by the MBS, or medications or treatment, including
parenteral nutrition not subsidized by the PBS (Table 5).
5. Conclusion
This data linkage study provides the ﬁrst comprehensive estimate
of healthcare use and its costs in SSc patients in Australia, and is
the largest study of its kind to date. We believe our ﬁndings are
applicable to other developed countries with a similar standard of
healthcare. SSc is associated with a substantial direct cost burden.
Table 6
Total healthcare cost in SSc.
Hospital cost
∗
Ambulatory care cost Medication cost
Total healthcare cost AUD$ USD$ AUD$ USD$ AUD$ USD$
Victorian SSc patients (n=1266)†
Total cost between 2011 and 2015 32,653,898.06 24,033,268.47 17,922,255.60 13,190,780.12 22,896,622.80 16,851,914.38
Total annual cost 6,530,779.61 4,806,653.69 3,584,451.12 2,638,156.02 4,579,324.56 3,370,382.88
Total annual cost per patient 5,158.59 3,796.72 2,831.32 2,083.85 3617.16 2662.23
Australian SSc patients (n=5129)†
Total cost between 2011 and 2015 132,292,135.17 97,376,009.45 72,609,201.40 53,440,372.23 92,762,068.20 68,272,882.2
Total annual cost 26,458,427.04 19,473,401.90 14,521,840.30 10,688,074.46 18,552,413.60 13,654,576.41
Total annual cost per patient 5,158.59 3,796.72 2,831.32 2,083.85 3617.16 2662.23
Total health service cost AUD$ (n=5129) USD$ (n=5129)
Total cost between 2011 and 2015 297,663,404.77 219,080,200.42
Annual cost 59,532,680.95 43,816,040.08
Total annual cost per patient 11,607.07 8542.80
ASCS=Australian Scleroderma Cohort Study, AUD=Australian Dollar, ED=emergency department, SSc= systemic sclerosis, USD=US dollar.
∗
Hospital cost is the total cost of hospitalizations and ED presentation cost.
† The proportion of SSc patients recruited in ASCS was estimated relative to the predicted prevalence of SSc in Australia (21.1 per 100,000)[14,15] and population data from the Australian Bureau of Statistics
(Victorian population of 5,996,400, Australian population of 24,304,682 in 2015).[10] Extrapolation to total cost to the Australian government was based on the estimated number of SSc patients in Victoria (n=
1266) and in Australia (n=5129). Costs are also presented in USD based on currency conversion performed on May 10th, 2017.
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Economic studies such as ours will allow the development of
tailored policies to improve patient care and associated costs, and
reduce the long-term impact of this devastating disease.
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